Clinical Trial

ColoSense Post-Approval Study

Recruiting
View on ClinicalTrials.gov →
Summary
The post-approval study (PAS) described here will supplement existing data generated in the CRC-PREVENT clinical trial. The primary outcomes of this supplemental study will include: clinical sensitivity, clinical specificity, positive predictive value (PPV), and negative predictive value (NPV) of ColoSense.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-14.
Status change: Not Yet Recruiting → Recruiting 2025-11-18
Trial Details
NCT Number NCT07069556
Lead Sponsor Geneoscopy, Inc.
Conditions Colorectal Cancer (Diagnosis)
Enrollment 12,500 participants
Start Date 2025-09-05
Primary Completion 2028-09-01 (estimated)
Study Completion 2030-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-21